The illustration of protein structure (domains) on the left side, and corresponding exons in the FLT3 gene are displayed on the right side. FMS-like tyrosine kinase 3 (FLT3) mutations represent some ...

This model illustrates how SETD1B promotes the expansion of H3K4me3 epigenetic marks and upregulates MYC expression, driving cytokine-independent cell growth in FLT3-mutated AML. Acute myeloid ...

Data from Phase 3 MORPHO trial selected for press briefing and to be presented as oral session during the 2023 European Hematology Association (EHA) Hybrid Congress Exploratory results demonstrated ...

Panelists discuss how current NCCN guidelines emphasize the importance of treating AML at experienced centers with proper infrastructure, while treatment decisions are based on intensive vs ...

Preliminary data supports BMF-500’s potential as a transformative therapy for patients with FLT3 mutated relapsed or refractory (R/R) acute leukemia BMF-500 showed a favorable safety and tolerability ...

Post-HSCT gilteritinib maintenance in R/R FLT3-mutated AML showed encouraging OS and relapse-free survival ranges, suggesting a possible survival advantage versus historical cohorts without ...

Led by Professor Anskar Leung Yu-hung, a HKUMed study shows that the combined use of the FLT3 inhibitor Quizartinib and the ...

While patients with acute myeloid leukemia (AML) are routinely treated with chemotherapy and other cell-killing therapies, existing options do not lead to favorable clinical outcomes in all patients.

- Presentations include pooled post-hoc analysis of the Phase 3 ADMIRAL and COMMODORE data on post-transplant gilteritinib resumption in relapsed or refractory FLT3m+ AML - - Findings from the Phase 3 ...

New research from the real-world setting supports key thresholds of measurable residual disease (MRD) negativity in NPM1-mutated acute myeloid leukemia (AML) that can predict disease relapse. The ...